Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Haisco Pharmaceutical Group is the lead sponsor of 35 current clinical trials in our China register. 21 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are HSK31858, HSK39004 Dry and HSK39004. The most-studied condition is COPD (Chronic Obstructive Pulmonary Disease).

ClinicalTrials.gov trials by status

Recruiting2160%
Not yet open720%
Active, closed411%
By invitation39%

Trials by phase

Phase 11337%
Phase 21234%
Phase 3617%
Phase 1/226%
Phase 413%
Not applicable13%

Clinical trials sponsored by Haisco Pharmaceutical Group

35 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Phase I Study of HSK41959 in Solid Tumors With MTAP Deletion NCT06968572 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Drug: HSK41959	Phase 1	Recruiting	2025-04	China
Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN NCT07363460 · ClinicalTrials.gov ↗ · Lupus Nephritis (LN) Drugs: HSK39297 200mgQD, HSK39297 300mgQD	Phase 2	Recruiting	2025-11	China
HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer NCT07790510 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer (CRC) Drugs: Cetuximab, Folfiri, HSK42360-Na	Phase 1/2	Recruiting	2026-08	China
A Study to Evaluate the Accuracy of aTCI Model of Cipepofol in Patients With General Anesthesia During Elective Surgery NCT06740201 · ClinicalTrials.gov ↗ · Anesthesia	Phase 4	Recruiting	2025-01	China
Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation NCT06050980 · ClinicalTrials.gov ↗ · NSCLC	Phase 1	Recruiting	2023-03	China
A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Abdominal Surgery NCT07533786 · ClinicalTrials.gov ↗ · Pain After Surgery Drugs: HSK55718, Morphine	Phase 2	Recruiting	2026-05	China
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPD NCT07583849 · ClinicalTrials.gov ↗ · COPD (Chronic Obstructive Pulmonary Disease) Drugs: HSK39004 Dry, HSK39004 Dry Simulant	Phase 3	Recruiting	2026-05	China
Phase I Study of HSK46575 in Patients With Metastatic Castration-Resistant Prostate Cancer NCT07007910 · ClinicalTrials.gov ↗ · m CRPC	Phase 1	Recruiting	2024-12	China
Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic Impairment NCT07152288 · ClinicalTrials.gov ↗ · Paroxysmal Nocturnal Hemoglobinuria (PNH) Drug: HSK39297	Phase 1	Recruiting	2025-05	China
A Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT07283796 · ClinicalTrials.gov ↗ · NHL	Phase 1	Recruiting	2025-08	China
Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation NCT07158710 · ClinicalTrials.gov ↗ · Malignant Brain Tumors Drug: HSK42360	Phase 1	Recruiting	2025-08	China
A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis NCT06660992 · ClinicalTrials.gov ↗ · Non-cystic Fibrosis Bronchiectasis Drug: HSK31858	Phase 3	Recruiting	2024-09	China
Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation NCT07561554 · ClinicalTrials.gov ↗ · Solid Tumors (Phase 1) Drug: HSK42360-Na	Phase 1	Recruiting	2026-03	China
Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN NCT07390123 · ClinicalTrials.gov ↗ · IgA Nephropathy (IgAN) Drug: HSK39297	Phase 3	Recruiting	2026-04	China
Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD) NCT07140328 · ClinicalTrials.gov ↗ · Chronic Obstructive Lung Disease (COLD) Drugs: HSK39004, HSK39004 Dry	Phase 2	Recruiting	2025-04	China
A Study to Assess the Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis NCT07616375 · ClinicalTrials.gov ↗ · Non-cystic Fibrosis Bronchiectasis Drug: HSK31858	Phase 3	Recruiting	2025-09	China
Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria NCT06745622 · ClinicalTrials.gov ↗ · Paroxysmal Nocturnal Hemoglobinuria	Phase 2	Recruiting	2025-01	China
A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy NCT07616700 · ClinicalTrials.gov ↗ · IgA Nephropathy (IgAN) Drugs: HSK39297 200mgQD, HSK39297 300mgQD	Phase 2	Recruiting	2025-08	China
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and the Food Effect of HSK55879 Tablets in Healthy Subjects. NCT07521345 · ClinicalTrials.gov ↗ · Healhty	Phase 1	Recruiting	2026-03	China
Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation NCT06536400 · ClinicalTrials.gov ↗ · Solid Tumors Drug: HSK42360	Phase 1	Recruiting	2024-06	China
A Study for HSK47388 in Participants With Ulcerative Colitis NCT07335055 · ClinicalTrials.gov ↗ · Ulcerative Colitis (UC)	Phase 2	Recruiting	2026-02	China
A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis NCT07150988 · ClinicalTrials.gov ↗ · Psoriasis Drug: HSK44459	Phase 2	Not yet open	2025-09	China
HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion NCT07699757 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC), Advanced Solid Tumors Drugs: Carboplatin, Cisplatin/carboplatin, Docetaxel	Phase 1	Not yet open	2026-07	China
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of HSK46256 in Patients With Advanced Solid Tumors NCT07695142 · ClinicalTrials.gov ↗ · Advanced Solid Tumor (Phase 1)	Phase 1	Not yet open	2026-07	China
Long-Term Safety and Efficacy of HSK39004 Inhalation Suspension in COPD NCT07634367 · ClinicalTrials.gov ↗ · COPD (Chronic Obstructive Pulmonary Disease) Drug: HSK39004	Phase 3	Not yet open	2026-07	China
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of HSK39004 Inhalation Suspension in Patients With COPD NCT07658339 · ClinicalTrials.gov ↗ · COPD (Chronic Obstructive Pulmonary Disease) Drug: HSK39004	Phase 3	Not yet open	2026-07	China
A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Study Comparing the Efficacy and Safety of Cofrogliptin Versus Acarbose in Drug-Naïve Patients With Type 2 Diabetes NCT07122102 · ClinicalTrials.gov ↗ · Type 2 Diabetes Drugs: Acarbose, Cofrogliptin	Not applicable	Not yet open	2025-10	China
Long-Term Safety and Efficacy of HSK39004 Dry Powder Inhaler in COPD NCT07425210 · ClinicalTrials.gov ↗ · Chronic Obstructive Lung Disease (COLD) Drug: HSK39004 Dry	Phase 2	Not yet open	2026-03	China
A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Bronchial Asthma NCT06637254 · ClinicalTrials.gov ↗ · Bronchial Asthma Drug: HSK31858	Phase 2	By invitation	2024-10	China
A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Airway Mucus Hypersecretion NCT06820749 · ClinicalTrials.gov ↗ · Asthma Bronchiale, Bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD) Drug: HSK31858	Phase 2	By invitation	2024-12	China
Clinical Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HSK31858 in Healthy Subjects NCT07134465 · ClinicalTrials.gov ↗ · Healthy Subjects	Phase 1	By invitation	2025-08	China
Clinical Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of HSK31858 in Healthy Subjects NCT07134478 · ClinicalTrials.gov ↗ · Healthy Subjects	Phase 1	Active, closed	2024-10	China
A Clinical Study Evaluating the Pharmacokinetics and Pharmacodynamics of HSK39004 Inhalation Suspension in COPD Patients NCT07331402 · ClinicalTrials.gov ↗ · COPD Patients	Phase 2	Active, closed	2025-07	China
Trial of HSK44459 Cream for the Management Plaque Psoriasis NCT07623486 · ClinicalTrials.gov ↗ · Psoriasis Drug: HSK44459	Phase 1/2	Active, closed	2026-05	China
Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD) NCT07108699 · ClinicalTrials.gov ↗ · Chronic Obstructive Pulmonary Disease (COPD) Drugs: HSK39004 Dry, HSK39004 Dry Simulant	Phase 2	Active, closed	2025-08	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Haisco Pharmaceutical Group trials

26 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Conditions in Haisco Pharmaceutical Group trials

30 conditions

COPD (Chronic Obstructive Pulmonary Disease)3 Advanced Solid Tumors2 Psoriasis2 Healthy Subjects2 Chronic Obstructive Pulmonary Disease (COPD)2Non-cystic Fibrosis Bronchiectasis2IgA Nephropathy (IgAN)2Chronic Obstructive Lung Disease (COLD)2Non-Small Cell Lung Cancer1Pancreatic Ductal Adenocarcinoma (mPDAC)1Lupus Nephritis (LN)1 Metastatic Colorectal Cancer (CRC)1 Anesthesia1COPD Patients1Bronchial Asthma1Advanced Solid Tumor (Phase 1)1NSCLC1Pain After Surgery1Asthma Bronchiale1Bronchiectasis1m CRPC1Paroxysmal Nocturnal Hemoglobinuria (PNH)1NHL1Malignant Brain Tumors1

By trial register

Register	Trials	Recruiting
Clinical trials in China	35	21

A trial with sites in more than one country appears in each of those registers.

Other sponsors in COPD (Chronic Obstructive Pulmonary Disease)

Sponsor	Trials
Joincare Pharmaceutical Group Industry	2
Sir Run Run Shaw Hospital	2
Generate Biomedicines	1
Ganzhou Hemay Pharmaceutical	1

Sponsors with the most current trials registered for this condition.

Questions about Haisco Pharmaceutical Group trials

How many clinical trials does Haisco Pharmaceutical Group sponsor?

Haisco Pharmaceutical Group is the lead sponsor of 35 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Haisco Pharmaceutical Group trials recruiting?

Yes. 21 of its 35 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Haisco Pharmaceutical Group testing?

Its current trials name 26 drugs and biologicals as interventions. The most frequent are HSK31858 (4), HSK39004 Dry (4), HSK39004 (3), HSK39004 Dry Simulant (2) and HSK39297 (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Haisco Pharmaceutical Group clinical trials